Urica Therapeutics Announces Topline Data From The Phase 1 Clinical Trial Evaluating Dotinurad In Healthy Volunteers In The U.S.
Portfolio Pulse from Benzinga Newsdesk
Urica Therapeutics has announced topline data from its Phase 1 clinical trial of Dotinurad in healthy volunteers in the U.S. The data shows comparable pharmacokinetic, pharmacodynamic, and safety profiles between U.S. and Japanese healthy subjects. The company is initiating a Phase 1b clinical trial in gout patients in the U.S. and expects to begin pivotal clinical trials in 2024.
June 29, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Fortress Biotech (FBIO) may see a positive impact as Urica Therapeutics, a company it has a stake in, has announced positive Phase 1 clinical trial results for Dotinurad.
Fortress Biotech (FBIO) is likely to be positively impacted by this news as it has a stake in Urica Therapeutics. The positive Phase 1 clinical trial results for Dotinurad indicate progress in the drug's development, which could potentially lead to future revenues for FBIO if the drug is successfully commercialized.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80